Share Performance

Stock Quote & Chart

Stock Quote | Stock Chart | Investment Calculator | Historical Lookup
Recent Newsmore >
03/27/17
Nabriva Therapeutics to Present at the Needham and Company 16th Annual Healthcare Conference
VIENNA, Austria and KING OF PRUSSIA, Pa., March 27, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics AG (NASDAQ:NBRV), a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics, today announced that Colin Broom, M.D., chief executive officer of Nabriva Therapeutics, will provide a company overview and business update at the Needham and Company 16th Annual Hea... 
03/24/17
Nabriva Therapeutics Provides Business and Development Update and Reports 2016 Financial Results
VIENNA, Austria and KING OF PRUSSIA, Pa., March 24, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics AG (NASDAQ:NBRV), a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics, today provided a business and clinical development update and reported its financial results for the year ended December 31, 2016. “For the last 12 months, we have been executing o... 
02/27/17
Nabriva Therapeutics to Present at the Cowen and Company 37th Annual Healthcare Conference
VIENNA, Austria and KING OF PRUSSIA, Pa., Feb. 27, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics AG (NASDAQ:NBRV), a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics, today announced that Colin Broom, M.D., chief executive officer of Nabriva Therapeutics, will provide a company overview and business update at the Cowen and Company 37th Annual Health...